Financial Performance - Arcturus Therapeutics reported a quarterly loss of $0.49 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of +60.80% [1] - The company posted revenues of $17.15 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 50.63%, although this is a decline from $41.67 million in the same quarter last year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Arcturus Therapeutics shares have declined approximately 48.6% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.49 on revenues of $9.77 million, and for the current fiscal year, it is -$3.49 on revenues of $73.55 million [7] - The earnings outlook and estimate revisions will be crucial for assessing the stock's future performance [4][5] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcturus belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Arcturus may also be influenced by the overall industry trends and the performance of peer companies, such as TScan Therapeutics, which is expected to report a quarterly loss of $0.35 per share [9]

分组1 - Telos Corporation reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to a loss of $0.1 per share a year ago, representing an earnings surprise of +350.00% [1] - The company achieved revenues of $51.44 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 13.06%, and showing a significant increase from year-ago revenues of $23.78 million [2] - Telos has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] 分组2 - The stock has gained approximately 86.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $45.8 million, while for the current fiscal year, it is -$0.03 on revenues of $157.89 million [7] - The Computers - IT Services industry, to which Telos belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]

Core Insights - Envoy Medical, Inc. reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -29.63% [1] - The company generated revenues of $0.04 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 23.64% [2] - Envoy Medical's shares have declined approximately 50.9% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $0.06 million, and for the current fiscal year, it is -$1.17 on revenues of $0.2 million [7] Market Outlook - The earnings outlook and estimate revisions trend for Envoy Medical were favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The Medical - Instruments industry, to which Envoy Medical belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a positive industry outlook [8]

Core Insights - ReNew Energy Global PLC reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.17 per share, representing an earnings surprise of -23.53% [1] - The company posted revenues of $408 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.17% and showing an increase from $356 million year-over-year [2] - The stock has gained approximately 10.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 14.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $318 million, while for the current fiscal year, the estimate is $0.23 on revenues of $1.59 billion [7] - The estimate revisions trend for ReNew Energy Global was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Alternative Energy - Other industry, to which ReNew Energy Global belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - 908 Devices Inc. reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, but an improvement from a loss of $0.23 per share a year ago [1] - The company achieved revenues of $14.01 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.17%, although this represents a decline from $16.77 million in the same quarter last year [2] - The stock has increased approximately 235.5% year-to-date, significantly outperforming the S&P 500's gain of 14.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $17.06 million, and for the current fiscal year, it is -$0.86 on revenues of $55.42 million [7] - The estimate revisions trend for 908 Devices was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which 908 Devices belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Telus reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share, and down from $0.21 per share a year ago, representing an earnings surprise of -10.53% [1] - The company posted revenues of $3.71 billion for the quarter ended September 2025, which was 0.27% below the Zacks Consensus Estimate and a decrease from $3.74 billion year-over-year [2] - Telus has surpassed consensus EPS estimates two times over the last four quarters and has topped consensus revenue estimates only once during the same period [2] Earnings Outlook - The sustainability of Telus's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $3.9 billion, and for the current fiscal year, it is $0.72 on revenues of $14.97 billion [7] Industry Context - The Zacks Industry Rank for Diversified Communication Services, which includes Telus, is currently in the bottom 21% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Telus's stock performance [5][6]

Core Viewpoint - Sanuwave Health Inc. reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing a significant improvement from a loss of $6.49 per share a year ago [1] Financial Performance - The company achieved revenues of $11.45 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.18%, and up from $9.36 million in the same quarter last year [2] - Over the last four quarters, Sanuwave Health has exceeded consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Performance - Sanuwave Health shares have increased approximately 14.8% since the beginning of the year, compared to a 14.3% gain in the S&P 500 [3] Future Outlook - The company's earnings outlook will be crucial for investors, with current consensus EPS estimates at $0.20 for the coming quarter and $0.34 for the current fiscal year, alongside projected revenues of $13.5 million and $44.44 million respectively [7] - The estimate revisions trend for Sanuwave Health was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Sanuwave Health belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - Claritev Corporation reported a quarterly loss of $4.07 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.12, and compared to a loss of $1.85 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $245.96 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.87% and showing an increase from $230.49 million in the same quarter last year [2] - Claritev Corporation's shares have increased approximately 319.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$3.07 on revenues of $236.34 million, and for the current fiscal year, it is -$14.36 on revenues of $943.77 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Fluor (FLR) reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.44 per share, and showing an increase from $0.51 per share a year ago, representing an earnings surprise of +54.55% [1][2] Financial Performance - The company posted revenues of $3.37 billion for the quarter ended September 2025, which missed the Zacks Consensus Estimate by 18.21% and decreased from $4.09 billion year-over-year [2] - Over the last four quarters, Fluor has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Performance - Fluor shares have declined approximately 9.6% since the beginning of the year, contrasting with the S&P 500's gain of 14.3% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.47 on revenues of $4.29 billion, and for the current fiscal year, it is $2.03 on revenues of $16.37 billion [7] - The outlook for the Engineering - R and D Services industry, where Fluor operates, is currently in the bottom 38% of Zacks industries, which may negatively impact stock performance [8]

Core Insights - The Joint Corp. reported quarterly earnings of $0.02 per share, exceeding the Zacks Consensus Estimate of a loss of $0.01 per share, representing an earnings surprise of +300.00% [1] - The company posted revenues of $13.38 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.84%, but down from $30.2 million year-over-year [2] - The stock has underperformed the market, losing about 22% since the beginning of the year compared to the S&P 500's gain of 15.6% [3] Earnings Performance - Over the last four quarters, The Joint has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the coming quarter is $0.16 on revenues of $15.04 million, and for the current fiscal year, it is $0.03 on revenues of $54.63 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for The Joint is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - HMOs industry, to which The Joint belongs, is currently in the bottom 27% of over 250 Zacks industries, suggesting potential challenges ahead [8]